文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

立体定向放射外科联合免疫检查点抑制剂治疗脑转移瘤:个体患者数据国际荟萃分析

Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data.
PubMed 文献 · Radiother Oncol · 2018-09-18

该国际个体患者数据荟萃分析纳入15家机构17项研究共534例脑转移瘤患者(1570个病灶),比较立体定向放射外科(SRS)与免疫检查点抑制剂(ICI)同期与不同期给药的结局。同期治疗1年总生存率64.6%高于不同期51.6%(p<0.001),1年局部控制率分别为89.2%与67.8%(p=0.09),1年区域脑控制率同期38.1%高于SRS前ICI给药12.3%(p=0.049),放射性坏死总发生率5.3%。作者认为同期SRS/ICI可能改善安全性与疗效,但结论为假设生成性,需进一步验证。

要点

  • 同期SRS/ICI组1年OS 64.6% vs 不同期组51.6%(p<0.001)。
  • 同期组1年LC 89.2% vs 不同期组67.8%(p=0.09)。
  • 同期组1年RBC 38.1% vs SRS前ICI组12.3%(p=0.049)。

核心结论

  • 同期给予SRS/ICI可能较序贯治疗改善安全性与疗效,但该发现为假设生成性,需正在开展和计划中的前瞻性试验进一步验证。

研究设计与样本

  • 采用PICOS/PRISMA/MOOSE选择方案,纳入3个国家15家机构的17项研究。
  • 纳入标准为诊断为脑转移瘤、接受SRS/ICI同期或非同期治疗、且报告至少一项主要或次要结局指标的患者。
  • 采用DerSimonian and Laird法进行加权随机效应荟萃分析。
  • 主要结局为1年总生存(OS),次要结局为1年局部控制(LC)、1年区域脑控制(RBC)和放射性坏死发生率。

主要发现

  • 共纳入534例患者,1570个脑转移瘤病灶。
  • 同期治疗组1年OS 64.6% vs 非同期治疗组51.6%(p<0.001)。
  • 同期治疗组1年LC 89.2% vs 非同期治疗组67.8%(p=0.09)。
  • 同期治疗组1年RBC 38.1% vs SRS前给予ICI组12.3%(p=0.049)。
  • 所有研究中放射性坏死总体发生率为5.3%。

局限性

  • 作者指出这些发现为假设生成性,需要正在开展和计划中的前瞻性试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: While the combination of stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain metastases (BM), there is a paucity of prospective data to validate both the safety and efficacy, as well as the optimal timing of these two therapies relative to one another. METHODS: A PICOS/PRISMA/MOOSE selection protocol was used to identify 17 studies across 15 institutions in 3 countries. Inclusion criteria were patients: diagnosed with BM; treated with SRS/ICI, either concurrently or non-concurrently; with at least one of the primary or secondary outcome measures reported. Weighted random effects meta-analyses using the DerSimonian and Laird method were performed. The primary outcome was 1-year overall survival (OS). Secondary outcomes were 1-year local control (LC), 1-year regional brain control (RBC), and radionecrosis incidence. RESULTS: A total of 534 patients with 1,570 BM were included. The 1-year OS was 64.6% and 51.6% for concurrent and non-concurrent therapy, respectively (p < 0.001). Local control at 1-year was 89.2% and 67.8% for concurrent and non-concurrent therapy, respectively (p = 0.09). The RBC at 1-year was 38.1% and 12.3% for concurrent and ICI administration prior to SRS, respectively (p = 0.049). The overall incidence of radionecrosis for all studies was 5.3%. CONCLUSIONS: Concurrent administration of SRS/ICI may be associated with improved safety and efficacy versus sequential therapy. These findings, however, are hypothesis-generating and require further validation by ongoing and planned prospective trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lehrer EJ, Peterson J, Brown PD, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiother Oncol. 2018. PMID: 30241791. doi:10.1016/j.radonc.2018.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。